Former Schering-Plough CEO elected to Bausch & Lomb BOD
ROCHESTER, N.Y. Former Schering-Plough chairman and CEO Fred Hassan has been elected to the board of Bausch & Lomb, the eyecare company reported Thursday.
“Bausch & Lomb and its customers will benefit from Fred Hassan’s extensive global business experience and his in-depth knowledge of the healthcare industry,” stated Gerald Ostrov, chairman and CEO, Bausch & Lomb. “We will especially value [Hassan’s] insights as we develop and market innovative pharmaceutical products for the global eye health industry.”
Hassan was chairman and CEO of Schering-Plough Corporation from 2003 until its acquisition by Merck earlier this month. Before joining Schering-Plough, he served as chairman and CEO of Pharmacia until that company was acquired by Pfizer in 2003.
It’s 2 Cool introduces personal cooling towelette
SAN ANTONIO, Texas It’s 2 Cool recently launched Cool Off, a personal cooling towelette that refreshes and renews anytime a quick cool down is needed.
Consumers wipe Cool Off on the skin and then press for few seconds to build the chill. Consumers report feeling cooling effects up to an hour and a half, with the average Cool Off chill lasting 20 minutes.
The towelettes are infused with a blend of natural cooling herbs, essential oils and moisturizing botanicals sealed with a fresh scent. Each towelette is packaged in single-use convenient and portable packet (2.5” wide x 3.5” tall).
According to consumer research, consumers would look for Cool Off in retail establishments in either the home/health category near the first aid or sports products, or the health and beauty aid category near the skin and sun care products.
Some 77% would use Cool Off as often as four times per week, the company reported with 40% reporting they would use the product one or more times a day.
Consumers participating in research projects have reported they would keep Cool Off packets on hand in their car, gym/sports bags, totes/purses, bike/golf bags and even in their pocket.
Study: Low-dose aspirin may not lessen cardiovascular disease risk
LONDON According to a meta-analysis published last week in the medical journal BMJ, low-dose aspirin may not be effective in lowering cardiovascular disease risk in the diabetes population.
The meta-analysis included six randomized trials of aspirin compared with placebo or no aspirin in people with diabetes and no pre-existing heart disease, encompassing more than 10,000 participants.
Researchers found no statistically significant reduction in the risk of major cardiovascular events when aspirin was compared with placebo across these six studies.
Researchers concluded that a clear benefit of aspirin in the primary prevention of major cardiovascular events in people with diabetes has yet to be clinically established.